Anandamide in health and disease /
A complete reference on the roles of anandamide in health and disease states. Following the characteristics of the series, this book provides a comprehensive overview of the effects of the mediator on human health. The book is divided into two parts, the first of which provides background informatio...
Kaydedildi:
| Diğer Yazarlar: | |
|---|---|
| Materyal Türü: | Elektronik Ekitap |
| Dil: | İngilizce |
| Baskı/Yayın Bilgisi: |
London ; San Diego, CA :
Academic Press,
[2025]
|
| Seri Bilgileri: | Molecular mediators in health and disease: how cells communicate
|
| Konular: | |
| Online Erişim: | ScienceDirect |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|
İçindekiler:
- Front Cover
- Anandamide in Health and Disease
- Molecular Mediators in Health and Disease: How Cells Communicate
- Anandamide in Health and Disease Molecular Mediators in Health and Disease: How Cells Communicate
- Copyright
- Contents
- Contributors
- An introduction to the role of anandamide in health and disease
- Disclosures
- References
- Series preface
- I
- Introduction to anandamide
- 1
- Regulation of the levels of anandamide and its bioactive congeners by biosynthesis and degradation
- 1. Introduction. Discovery and biological role of anandamide and its congeners
- 2. Biosynthesis of anandamide and its congeners
- 3. Inactivation of anandamide and its congeners
- 3.1 Hydrolysis
- 3.2 Oxidation of anandamide by various enzymatic pathways
- 4. SNPs of the main enzymes specifically involved in N-acyl-ethanolamine biosynthesis and degradation
- 5. Therapeutic manipulation of anandamide and N-acyl-ethanolamine levels through pharmacological and dietary interventions
- 6. Conclusions
- References
- 2
- Imaging the endocannabinoid enzyme fatty acid amide hydrolase in the living human brain
- 1. Harvesting the therapeutic potential of fatty acid amide hydrolase
- 2. Fatty acid amide hydrolase
- 3. The development of FAAH inhibitors
- 4. Trials with FAAH inhibitors in humans
- 5. Positron emission tomography as a tool to investigate FAAH in vivo
- 6. Development of PET radiotracers for FAAH
- 7. PET radiotracers for FAAH not yet translated to human
- 8. Human PET imaging of [11C]CURB for the key endocannabinoid enzyme FAAH
- 9. Conclusions and future direction
- References
- 3
- Anandamide: From modulation of neuronal excitation to antimicrobial activities-What is in common?
- 1. Introduction
- 2. Biosynthesis of Anandamide and its metabolism
- 2.1 Anandamide production.
- 6.3 Anandamide interferes with daughter cell separation during Staphylococcus aureus cell division
- 6.4 Anandamide alters bacterial membrane properties
- 6.4.1 Anandamide induces immediate changes in the bacterial membrane potential
- 6.4.2 Anandamide reduces membrane incorporation of the membrane fluidity probe laurdan
- 6.4.3 Anandamide increases the proportion of cardiolipin in the bacterial membrane
- 6.5 Anandamide inhibits membrane ATPase activity
- 6.6 Anandamide reduces the cell wall teichoic acid content
- 6.7 Antibiofilm effect of anandamide
- 6.7.1 Role of altered membrane potential for the antibiofilm effect of anandamide
- 6.7.2 The role of reduced RNAIII transcript levels for the antibiofilm effect of anandamide
- 6.7.3 The role of reduced autolysin and increased ClpXP activities for the antibiofilm effect of anandamide
- 6.7.4 Anandamide reduces exopolysaccharide production but increases extracellular DNA (eDNA)
- 6.8 Anandamide sensitizes MRSA and MDRSA to antibiotics
- 7. Antifungal effects of anandamide
- 8. Conclusions
- References
- II
- Anandamide in diseases
- 4
- Anandamide and mood disorders
- 1. Introduction
- 2. Fundamentals of N-arachidonoylethanolamine as a signaling molecule
- 2.1 AEA biosynthesis and catabolism
- 2.2 Receptor targets of AEA:CB1R
- 2.3 Receptor targets of AEA: Transient receptor potential vanilloid 1
- 2.4 Interactions between CB1R and TRPV1 signaling
- 2.5 Other receptor targets of AEA
- 3. AEA-mediated signaling in brain regions essential for mood regulation
- 3.1 AEA signaling in the amygdala
- 3.2 AEA signaling: PFC
- 3.3 AEA signaling: Hippocampus
- 3.4 Interactions between AEA and dopamine signaling
- 4. AEA-mediated regulation of the hypothalamic-pituitary adrenal axis
- 5. Preclinical, behavioral studies.
- 5.1 AEA-mediated regulation of behavioral responses to acute stress
- 5.2 Role of AEA in brain plasticity associated with chronic stress and trauma
- 5.3 Role of AEA in fear memories
- 5.4 Role of AEA in depressive behaviors
- 6. Human studies
- 6.1 Circulating AEA concentrations
- 6.1.1 Effects of acute psychological and physiological stress on circulating AEA concentrations
- 6.1.2 Depression
- 6.1.3 Anxiety
- 6.1.4 Posttraumatic stress disorder
- 6.2 Genetic studies
- 7. Neurobiological associations
- 7.1 Amygdala
- 7.2 Hippocampus
- 7.3 Prefrontal cortex
- 7.4 Striatum
- 8. Clinical studies with FAAH inhibitors
- 9. Conclusions
- References
- 5
- Anandamide and anxiety
- 1. Introduction
- 2. Studies in healthy adults
- 2.1 Genetic influences on anandamide levels (FAAH C385A)
- 2.2 Anandamide levels in biological samples
- 2.3 Pharmacological manipulation of anandamide levels (FAAH inhibition)
- 3. Anxiety disorders
- 3.1 Genetic influences on anandamide levels (FAAH C385A)
- 3.2 Anandamide levels in biological samples
- 3.3 Pharmacological manipulation of anandamide levels (FAAH inhibition)
- 4. Clinical populations other than anxiety disorders
- 4.1 Genetic influences on anandamide levels (FAAH C385A)
- 4.2 Anandamide levels in biological samples
- 4.3 Pharmacological manipulation of anandamide levels (FAAH inhibition)
- 5. Overall conclusions: Is there a relationship between anandamide and anxiety?
- References
- 6
- Anandamide and disease. Role in stress, fear, and PTSD
- 1. Posttraumatic Stress Disorder
- 2. Mechanisms underlying PTSD
- 2.1 Stress reactivity
- 2.2 Fear extinction
- 3. Treatment of PTSD
- 4. Cannabinoids as treatments for PTSD
- 4.1 Cannabis use in PTSD
- 4.2 Cannabinoids in stress studies
- 4.3 Cannabinoids in fear conditioning studies.